Learn about MSSA bacteremia diagnosis, including clinical documentation requirements, ICD-10 codes (A41.01, A41.02), medical coding guidelines, and best practices for healthcare professionals. Understand the symptoms, treatment, and management of Methicillin-sensitive Staphylococcus aureus bloodstream infections for accurate and efficient clinical care. This resource provides essential information on MSSA bacteremia for physicians, nurses, coders, and other healthcare providers.
Also known as
Sepsis due to Methicillin susceptible S. aureus
Sepsis caused by MSSA bacteria.
Sepsis, unspecified organism
Sepsis without a specified causative organism.
Other specified abnormal findings of blood chemistry
Abnormal blood chemistry findings indicative of possible bacteremia.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the MSSA bacteremia primary?
When to use each related code
| Description |
|---|
| MSSA Bacteremia |
| MRSA Bacteremia |
| Staphylococcal Bacteremia NOS |
Coding sepsis without documented organ dysfunction when MSSA bacteremia is present leads to undercoding and lost revenue.
Overlooking complicating conditions like endocarditis or osteomyelitis with MSSA bacteremia impacts DRG assignment.
Misclassifying present on admission status for MSSA bacteremia can affect quality reporting and reimbursement.
Q: What are the recommended initial empiric antibiotics for Methicillin-Sensitive Staphylococcus Aureus (MSSA) bacteremia in adult patients, and how should treatment be adjusted based on culture and sensitivity results?
A: Initial empiric antibiotic therapy for MSSA bacteremia in adults should cover Staphylococcus aureus and should consider patient-specific factors like allergy status, source of infection, and local resistance patterns. Common choices include Nafcillin or Oxacillin IV. Vancomycin IV is an alternative for patients with beta-lactam allergies. Once culture and sensitivity results are available, therapy should be narrowed to the most effective agent based on the antibiogram. For example, if Cefazolin demonstrates sensitivity, it could be used as a step-down therapy. The duration of treatment depends on the source and severity of infection, ranging from 2-6 weeks for uncomplicated bacteremia to longer courses for complicated cases, such as endocarditis or osteomyelitis. Explore how our antimicrobial stewardship resources can help optimize antibiotic selection and duration for MSSA bacteremia.
Q: How do I differentiate MSSA bacteremia from contaminant Staph aureus in blood cultures, and what are the key clinical indicators to look for in making this distinction?
A: Differentiating true MSSA bacteremia from blood culture contamination requires careful consideration of clinical context and laboratory findings. True bacteremia is often associated with signs and symptoms of infection, such as fever, chills, hypotension, elevated white blood cell count, and elevated inflammatory markers (e.g., CRP, procalcitonin). Multiple positive blood cultures, particularly from different venipuncture sites, increase the likelihood of true bacteremia. Conversely, a single positive blood culture with a common skin commensal like coagulase-negative Staphylococcus, in the absence of clinical symptoms, suggests contamination. Furthermore, identifying the source of infection (e.g., indwelling catheter, surgical site) supports a diagnosis of true bacteremia. Consider implementing a standardized blood culture collection protocol to minimize contamination rates. Learn more about best practices for blood culture collection and interpretation.
Patient presents with signs and symptoms consistent with Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia. Clinical manifestations include fever, chills, tachycardia, hypotension, and possible focal infections such as endocarditis, osteomyelitis, or septic arthritis. Blood cultures drawn from two separate sites have confirmed the presence of MSSA. The patient's medical history includes [insert relevant past medical history, e.g., recent surgery, indwelling catheter, diabetes mellitus]. Differential diagnoses considered include other bacterial infections, viral infections, and inflammatory conditions. The diagnosis of MSSA bacteremia is based on positive blood cultures, clinical presentation, and exclusion of other potential etiologies. Treatment plan includes intravenous administration of appropriate antibiotics such as nafcillin, oxacillin, cefazolin, or vancomycin if there is a concern for penicillin allergy. The duration of antibiotic therapy will be determined based on clinical response and infection source control. Patient will be closely monitored for complications such as sepsis, septic shock, and end-organ damage. Further investigations may include echocardiography, bone scan, or joint aspiration depending on the suspected source of infection. ICD-10 code A41.01 (Sepsis due to Methicillin-susceptible Staphylococcus aureus) and relevant procedure codes for blood cultures and antibiotic administration will be documented for billing and coding purposes. Patient education provided on infection control measures and medication adherence. Follow-up appointments scheduled to monitor treatment response and assess for potential complications. Prognosis is generally favorable with prompt and appropriate antibiotic therapy.